This article focuses on how the immune system functions, the challenges that it presents to drug development and why there are such concerns around safety that need to be investigated in pre-clinical studies. Moreover, it covers the role of checkpoint inhibitors as an attractive target for cancer immunotherapy.
List view / Grid view
Greg Bannish - Vice President Biopharmaceutical Development Envigo
Filter the results